Centene Corp.

Centene Corp.

CNC

Get informed when a big investor buys or sells

+ Follow
Market Cap$30.13B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Centene Corp.Centene Corp.-4.7--30%0.20.8

Earnings Call Q1 2026

April 28, 2026 - AI Summary

Strong Q1 Performance and Adjusted EPS Increase: Centene reported a first-quarter adjusted diluted EPS of $3.37, exceeding expectations by nearly $0.50. This strong performance led to an increase in the full-year adjusted EPS outlook to greater than $3.40, up from greater than $3.00.
Operational Improvements in Medicaid: The Medicaid segment saw a strong performance with an HBR (Health Benefit Ratio) of 93.1%, improving by 50 basis points YOY. This was driven by improved medical cost trend management and beneficial factors such as a lighter flu season and better-than-expected utilization management.
Medicare Segment Outperformance: Both Medicare Advantage and PDP (Prescription Drug Plan) segments exceeded expectations, with the Medicare HBR reported at 84.9%. The trends in this segment are seen as encouraging, laying a path towards breakeven financial results by 2027, although high medical and pharmacy cost trends remain a concern.

Exclusive for Stockcircle Pro members

Sign upSign Up
$58.31

Target Price by Analysts

7.7% downsideCentene Target Price DetailsTarget Price
$94.99

Current Fair Value

50.4% upside

Undervalued by 50.4% based on the discounted cash flow analysis.

Share Statistics

Market cap$30.13 Billion
Enterprise Value$26.19 Billion
Dividend Yield$- (-)
Earnings per Share$-13.61
Beta1.09
Outstanding Shares492,069,000

Return

Return on Equity-30.07%ROE
Return on Assets-7.94%
Return on Invested Capital-15.66%

Valuation & Multiples

P/E Ratio-4.65P/E Ratio
PEG-26.51PEG
Price to Sales0.16Price to Sales
Price to Book Ratio1.47Price to Book Ratio
Enterprise Value to Revenue0.13
Enterprise Value to EBIT-4.07
Enterprise Value to Net Income-5
Total Debt to Enterprise0.66
Debt to Equity0.81Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
April 28, 2026
EPS Estimate
$2.23
Average shareholder expectation
Revenue Estimate
$47.53 B
Average shareholder expectation

Next Earnings Call

Expected Date
July 24, 2026
EPS Estimate
$1.11
Average shareholder expectation
Revenue Estimate
$47.07 B
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.8660 18.27%
Total Calls11,188,200 38.21%
Total Puts9,689,500 21.69%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %96.43% 0.58%
Total Invested$15.50B 21.08%
Investors Holding910 62.00%

ESG Score

No data

About Centene Corp.

CEO: Michael Neidorff

Relevant Senate Committees

Finance

Controls taxation, trade, and entitlement spending (Medicare, Medicaid). This committee is paramount, as it directly shapes the funding, regulatory framework, and tax environment for Centene's primary business lines.

Appropriations

Allocates discretionary federal spending. Its subcommittees determine precise funding for healthcare programs (Medicaid, Medicare), directly impacting Centene's revenues from government contracts.

Health, Education, Labor, and Pensions

Directly regulates health policy, drug approvals (FDA), and labor laws. This committee's decisions profoundly impact Centene's operational costs (labor), drug formularies, and overall healthcare market dynamics.

Budget

Drafts the budget resolution, directly influencing overall federal spending levels, including critical funding for Medicare and Medicaid programs that Centene heavily relies on for revenue.